Navigation Links
Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting

tions, risks that the Chemical, Manufacturing and Controls section of Discovery's New Drug Application will not satisfy the FDA, risks relating to the ability of Discovery or Discovery's third party manufacturers and development partners to manufacture or provide Discovery with adequate supplies of drug substances and expertise for completion of any of Discovery's clinical studies, risks related to the ability of Discovery and its collaborators to develop, manufacture and successfully commercialize products that combine Discovery's drug products with innovative aerosolization technologies, risks relating to drug manufacturing by Discovery, risks relating to the significant, time-consuming and costly research, development, pre-clinical studies, clinical testing and regulatory approval process for any products that Discovery may develop independently or with Discovery's collaboration arrangements, risks relating to the development by other companies of competing therapies and/or technologies, risks relating to reimbursement and health care reform, and risks relating to securities, product liability and other litigation. Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials, even after obtaining promising earlier trial results. Data obtained from tests are susceptible to varying interpretations, which may delay, limit or prevent regulatory approval. Those associated risks and others are further described in Discovery's filings with the Securities and Exchange Commission including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto.

Company Contact: Lisa Caperelli, Investor Relations 215-488-9413


'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Discoverys KL-4 Surfactant Technology Demonstrates Novel Anti-Inflammatory Properties
3. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
(Date:7/23/2014)... YORK , July 23, 2014  When it comes ... Wagner is ready to roll out the red carpet. ... welcome an influx of HAL 9000-like robots into our human ... right now, there,s a pressing need to apply new technologies ... The worldwide market for medical robotics is expected to increase ...
(Date:7/23/2014)... July 23, 2014 Research and Markets ... Medical Gloves (Exam and Surgical) Markets Worldwide 2014" ... http://photos.prnewswire.com/prnh/20130307/600769 The purpose of this report ... Disposable Medical (Exam and Surgical) Gloves. The report discusses ... these products. Topics covered include product definitions, ...
(Date:7/23/2014)... July 23, 2014  Lightlake Therapeutics Inc. ("Lightlake") ... based on its expertise in opioid antagonists, announced ... drug application ("IND") with respect to its naloxone-based ... today that it has received an additional commitment ... part of the National Institutes of Health ("NIH"), ...
Breaking Medicine Technology:Disposable Medical Gloves (Exam and Surgical) Markets Worldwide 2014 2Disposable Medical Gloves (Exam and Surgical) Markets Worldwide 2014 3Disposable Medical Gloves (Exam and Surgical) Markets Worldwide 2014 4Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 3
... Pharmaceuticals, Inc. (NASDAQ: IDIX ), a biopharmaceutical company ... treatment of human viral diseases, today announced that it has ... common stock. All of these shares are being sold by ... sole book-running manager and underwriter for the offering.  Idenix intends ...
... RSB Spine, LLC, today announced allowance of ... its line of InterPlate® cervical and lumbar intervertebral ... of the most common spinal procedures performed by ... numerous disc replacement implants," commented James M. Moran, ...
Cached Medicine Technology:Idenix Pharmaceuticals Announces Proposed Public Offering of Common Stock 2
(Date:7/23/2014)... Karen Pallarito HealthDay Reporter ... wild day for Obamacare, two federal appeals courts arrived at ... provided to millions of Americans who bought health insurance through ... the matter is headed for a showdown before the U.S. ... U.S. Appeals Court for the District of Columbia Circuit said ...
(Date:7/23/2014)... The European Vitamins Market report explains ... and projection of revenue. The market in Europe is ... to $1,202.08 million by 2018, at a CAGR of ... TOC of the European Vitamins Market report, to get ... provides a glimpse of the segmentation in the European ...
(Date:7/23/2014)... The European Bio fertilizers Market Report defines ... analysis and forecast of revenue. The bio fertilizers market ... 2,566.4 million in 2012 to $4,582.2 million by 2017, ... , Browse through the TOC of the European Bio ... in-depth analysis provided. , http://www.micromarketmonitor.com/market/europe-bio-fertilizer-4637178345.html , ...
(Date:7/23/2014)... Bethesda, MD (July 23, 2014) Statins, a class ... reduce a patient,s risk of developing Barrett,s esophagus, according ... , the official journal of the American ... risk reduction with statin use. , "Patients who received ... of having Barrett,s esophagus compared to non-users," said study ...
(Date:7/23/2014)... July 23, 2014 According to a ... by Form Factor (Integrated Circuit IP, SOC IP), Design ... Application, Geography and Verification IP - Forecast & Analysis ... is expected to grow at a CAGR of 12.6% ... 2020. , Browse more than 76 market data tables ...
Breaking Medicine News(10 mins):Health News:2 Courts, 2 Different Decisions on Key Obamacare Provision 2Health News:2 Courts, 2 Different Decisions on Key Obamacare Provision 3Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 5Health News:Europe Bio Fertilizer Market is Expected to Reach $4,582.2 Million in 2017 - New Report by MicroMarket Monitor 2Health News:Europe Bio Fertilizer Market is Expected to Reach $4,582.2 Million in 2017 - New Report by MicroMarket Monitor 3Health News:Europe Bio Fertilizer Market is Expected to Reach $4,582.2 Million in 2017 - New Report by MicroMarket Monitor 4Health News:Statin use decreases the risk of Barrett's esophagus 2Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 5Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 6
... a leading provider of laser vision correction services under ... center in Des,Moines, Iowa. This marks the 74th LasikPlus ... vision center in the state of Iowa.,LasikPlus vision centers ... Similar to other LasikPlus vision centers throughout the ...
... Highlights Myriad Opportunities for Using Wireless ... Efficiency and Accuracy of Patient Care, WALTHAM, Mass., ... intelligent wireless LANs (WLANs) for enterprises and,service providers, will ... Exhibition, taking place February 24-28 in Orlando, FL, to,showcase ...
... ECG Devices Help Healthcare Organizations Deliver Clinical ... Data Faster and ... Networks, the leading,global provider of intelligent wireless LANs (WLANs) ... Corporation,(Nasdaq: CSCX ) ( http://www.cardiacscience.com ), the leading ...
... of, CellCept Will Provide Effective Treatment Options, According ... ... Feb. 25 Decision Resources, one of the,world,s leading research ... entry and uptake of high-priced branded,agents will drive the systemic ...
... HealthVault Empowers Patients to Orchestrate Health ... ... the leading provider,of next generation healthcare connectivity solutions, today announced ... using Microsoft(R) HealthVault(TM), at the 2008 HIMSS,(Healthcare Information and Management ...
... Hyperion,Therapeutics, Inc. today announced that the first ... trial of AMMONUL(R) (sodium phenylacetate and sodium,benzoate) Injection ... hepatic,encephalopathy (HE). The randomized, double-blind study is designed ... standard of care in,hospitalized adults. The FDA has ...
Cached Medicine News:Health News:LCA-Vision Announces the Opening of its 74th LasikPlus Vision Center in Des Moines, Iowa 2Health News:Colubris Demonstrates Wide-Ranging Mobility Solutions for Healthcare 2Health News:Cardiac Science Corporation Selects Colubris Networks' Wireless Solution for its Portable Electrocardiograph 2Health News:Cardiac Science Corporation Selects Colubris Networks' Wireless Solution for its Portable Electrocardiograph 3Health News:Uptake of Branded Agents Will Drive the Systemic Lupus Erythematosus Drug Market to Quadruple to $1.4 Billion in 2016 2Health News:Kryptiq and Microsoft to Showcase Unprecedented Connectivity Between Consumers and Their Doctors at HIMSS '08 2Health News:Kryptiq and Microsoft to Showcase Unprecedented Connectivity Between Consumers and Their Doctors at HIMSS '08 3Health News:Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy 2Health News:Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy 3
Scorpio CR Knee is designed to address normal knee kinematics, range of motion (ROM) and polyethylene wear....
... TC-PLUS Solution tricompartmental total knee prosthesis stems ... arthroplasty. State-of-the-art design and manufacturing technologies have ... biomechanical function as well as a favorable ... insert to keep wear to a minimum. ...
... Knee System has been ... refined with the aid ... and manufacturing technology. Its ... stability, function, performance and ...
... image guided surgery system offers full-featured ... design and use. It provides unparalleled ... localize critical anatomy and plan optimal ... surgeons an easy-to-use, technologically advanced approach ...
Medicine Products: